- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Nanogen, Inc. (Nasdaq:NGEN), developer of molecular-biology and rapid diagnostic products, and Thermo Fisher Scientific Inc., the world leader in serving science, have entered into an agreement in which Thermo Fisher will be the exclusive provider of a variety of products used in gene-expression experiments. These products are based on Nanogen's second generation proprietary probe technology for real-time PCR (polymerase chain reaction) applications, the most widely used method for the amplification and measurement of DNA and RNA for molecular diagnostics and life science research.
The agreement covers both custom and standard catalog products based on Nanogen's technology for real-time PCR applications. This probe technology is used as a method of quantitative detection for specific DNA or RNA sequences in a biological sample and incorporates Nanogen's MGB (Minor Groove Binder) technology. The Minor Groove Binder is a crescent-shaped molecule that when coupled to an oligonucleotide probe stabilizes the detection-target duplex, improving efficiency and specificity compared to longer traditional probes.
"We're very excited to partner with Thermo Fisher Scientific for our probe technology," said Howard Birndorf, CEO of Nanogen. "Our proprietary probe technology has proven to provide better results than traditional PCR probe technology. We're proud to serve the rapidly growing needs of the research market through partners like Thermo Fisher, which can help researchers advance basic biology and develop new therapeutics."
David Eansor, president of the Life Science Research business at Thermo Fisher Scientific, added, "We are delighted to add Nanogen's Probe technology to our extensive range of genomic-analysis tools. The resulting products will complement our offering of gene-expression modulation tools, PCR reagents, plastics and instruments, creating a more complete genomic workflow solution for our customers."
Nanogen's MGB technology is licensed broadly in various fields and is now an integral component in thousands of PCR probe products. Nanogen has more than 35 reagent and kit products that are sold for clinical diagnostic use under the MGB Alertģ and Q-PCR Alertô brands.
About Nanogen, Inc.
Nanogen (Nasdaq:NGEN) has a strong product and proprietary technology base of diagnostic solutions for two of the fastest growing in vitro diagnostic (IVD) marketsómolecular diagnostics and rapid point-of-care testing. The company provides their innovative, high-quality diagnostic products to clinicians and physicians worldwide, making it easier to predict and diagnose diseases, ultimately improving patient care. Products include molecular diagnostic kits and reagents, and kits for rapid, point-of-care testing. Nanogen has pioneered research in areas involving biomedical markers, molecular biology and nanotechnology to bring better results to diagnostics and healthcare. For additional information please visit Nanogenís website at www.nanogen.com.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. (NYSE:TMO) is the world leader in serving science, enabling our customers to make the world healthier, cleaner and safer. With annual revenues of $10 billion, we have more than 30,000 employees and serve over 350,000 customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as environmental and industrial process control settings. Serving customers through two premier brands, Thermo Scientific and Fisher Scientific, we help solve analytical challenges from routine testing to complex research and discovery. Thermo Scientific offers customers a complete range of high-end analytical instruments as well as laboratory equipment, software, services, consumables and reagents to enable integrated laboratory workflow solutions. Fisher Scientific provides a complete portfolio of laboratory equipment, chemicals, supplies and services used in healthcare, scientific research, safety and education. Together, we offer the most convenient purchasing options to customers and continuously advance our technologies to accelerate the pace of scientific discovery, enhance value for customers and fuel growth for shareholders and employees alike. Visit www.thermofisher.com.
Nanogen Forward-Looking Statement
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether patents owned or licensed by Nanogen will be developed into products, whether the patents owned by Nanogen offer any protection against competitors with competing technologies, whether products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in Nanogenís Form 10-K or Form 10-Q most recently filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Nanogen disclaims any intent or obligation to update these forward-looking statements.
For more information, please click here
Nicholas Venuto, Chief Financial Officer, 858-410-4600
Kelly Gann, Marketing Communications, 858-410-4667
Copyright © Business Wire 2008If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Stealth nanocapsules kill Chagas parasites in mouse models June 22nd, 2016
FEI and University of Liverpool Announce QEMSCAN Research Initiative: University of Liverpool will utilize FEIís QEMSCAN technology to gain a better insight into oil and gas reserves & potentially change the approach to evaluating them June 22nd, 2016
French Research Team Helps Extend MRI Detection of Diseases & Lower Health-Care Costs: CEA, INSERM and G2ELab Brings Grenoble Regionís Expertise In Advanced Medicine & Magnetism Applications to H2020 IDentIFY Project June 21st, 2016